2018 - The Year of the BioTechs, page-645

I trust that Colour Collective will grow the brand in the US and that it will take as long as it takes.  The key issue for the US being that out of pocket expenses for further expansion in the US should be limited.  

The key message Cellmid must deliver to the market is that the anti-aging line is now profitable.  Up until now that has been impossible because the cost of the Australian sales team exceeded the revenue they earned ….. however with some apparent sales growth (locally) and Fillerina filling some cost gaps (pun intended) that should now change.

If the consolidated accounts don't transparently divide costs and revenues between the anti-aging business and the midkine business the supporting narrative will need to do so effectively.